Prana eyes Phase III for lead asset on Huntington's data
This article was originally published in Scrip
Executive Summary
Phase II data for Prana Biotechnology's investigational therapy PBT2 show that it is safe and tolerable, with enough suggestion of clinical efficacy in early to mid-stage Huntington's disease for the company to take it into Phase III. Shares in the firm were up by as much as 24% to $9.10 in trading on Nasdaq on the morning of 18 February.